Nuclear medicine program progress report for quarter ending March 31, 1991
In this report the first fabrication and evaluation of an activated carbon-based osmium-194/iridium-194 generator system is described. Iridium-194 (t{sub {1/2}} = 19.2 h) decays by {Beta}{sup {minus}} emission (E{sub max} = 2.24 MeV) and is a potential candidate for radioimmunotherapy. An important characteristic is availability of {sup 194}Ir from decay of reactor-produced {sup 194}Os (t{sub {1/2}} = 6 y). A novel gas thermochromatographic method was developed for the one step conversion of metallic Os to OsO{sub 4} and subsequent separation and purification of OsO{sub 4}, which was then converted to the K{sub 2}OsCl{sub 6} for generator loading. The yield and the elution profile of carrier-free {sup 194}Ir, and {sup 194}Os breakthrough were determined for a prototype generator which was evaluated over a 10 month-period.l During this period several agents were also supplied to Medical Cooperative investigators, including iodine-123-labelled and iodine-125-labelled fatty acid analogues for studies at the Brookhaven National Laboratory. In addition, gold-198 and tungsten-188/-rhenium-188 generators were shipped to various investigators for therapeutic studies involving tumor-specific antibodies. 19 refs., 3 figs.
- Research Organization:
- Oak Ridge National Lab., TN (United States)
- Sponsoring Organization:
- DOE; USDOE, Washington, DC (United States)
- DOE Contract Number:
- AC05-84OR21400
- OSTI ID:
- 5405032
- Report Number(s):
- ORNL/TM-11830; ON: DE91015942
- Country of Publication:
- United States
- Language:
- English
Similar Records
The {sup 194}Os/{sup 194}Ir generator: Production and purification of {sup 194}Os
Production of tungsten-188 and osmium-194 in a nuclear reactor for new clinical generators
Related Subjects
400703* -- Radiochemistry & Nuclear Chemistry-- Radioisotope Production
550601 -- Medicine-- Unsealed Radionuclides in Diagnostics
550604 -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIBODIES
BETA DECAY
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY
BETA-MINUS DECAY RADIOISOTOPES
CHALCOGENIDES
CHEMICAL PREPARATION
DAYS LIVING RADIOISOTOPES
DECAY
DESIGN
DISEASES
DOCUMENT TYPES
DRUGS
ELECTRON CAPTURE RADIOISOTOPES
EVEN-EVEN NUCLEI
EVEN-ODD NUCLEI
FABRICATION
GOLD 198
GOLD ISOTOPES
HEAVY NUCLEI
HOURS LIVING RADIOISOTOPES
INTERMEDIATE MASS NUCLEI
INTERNAL CONVERSION RADIOISOTOPES
IODINE 123
IODINE 125
IODINE ISOTOPES
IRIDIUM 194
IRIDIUM ISOTOPES
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
LABELLING
MANAGEMENT
MEDICINE
MINUTES LIVING RADIOISOTOPES
NATIONAL ORGANIZATIONS
NEOPLASMS
NUCLEAR DECAY
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ODD-ODD NUCLEI
ORNL
OSMIUM 194
OSMIUM COMPOUNDS
OSMIUM ISOTOPES
OSMIUM OXIDES
OXIDES
OXYGEN COMPOUNDS
PALLADIUM 103
PALLADIUM ISOTOPES
PROGRAM MANAGEMENT
PROGRESS REPORT
RADIOISOTOPE GENERATORS
RADIOISOTOPES
RADIOPHARMACEUTICALS
REFRACTORY METAL COMPOUNDS
RHENIUM 188
RHENIUM ISOTOPES
SECONDS LIVING RADIOISOTOPES
STABLE ISOTOPES
SYNTHESIS
TIN 117
TIN ISOTOPES
TRANSITION ELEMENT COMPOUNDS
TUNGSTEN 188
TUNGSTEN ISOTOPES
US AEC
US DOE
US ERDA
US ORGANIZATIONS
YEARS LIVING RADIOISOTOPES